Related Experiment Video

Updated: Dec 9, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K

The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19

Lauren A Callender1,2, Michelle Curran1,2, Stephanie M Bates1,3

  • 1Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.

Frontiers in Immunology
|September 9, 2020
PubMed

Insights

Individuals with pre-existing comorbidities face higher COVID-19 mortality risks due to immune dysfunction. Treatments for these conditions and COVID-19 present complex challenges for patients and healthcare systems.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Public Health

Background:

  • Pre-existing comorbidities significantly increase mortality risk in COVID-19 patients.
  • Comorbidities can impair immune responses to SARS-CoV-2 infection.
  • Therapies for comorbidities complicate COVID-19 treatment strategies.

Purpose of the Study:

  • To review immune dysfunction in SARS-CoV-2 infection.
  • To analyze the impact of comorbidities on COVID-19 development and progression.
  • To explore therapeutic challenges in co-infected patients.

Main Methods:

  • Literature review of immune responses to SARS-CoV-2.
  • Analysis of comorbidity effects on COVID-19 pathogenesis.
  • Examination of drug interactions and treatment limitations.

Main Results:

  • Comorbidities alter immune system function, worsening COVID-19 outcomes.
  • Underlying disease mechanisms and common medications exacerbate viral progression.
  • Limited treatment options exist for COVID-19 in patients with comorbidities.

Conclusions:

  • Immune dysfunction is a key factor in severe COVID-19 among those with comorbidities.
  • Managing COVID-19 in patients with pre-existing conditions requires careful consideration of disease and drug interactions.
  • Long-term therapeutic strategies need to address these complex patient needs.

Keywords:
COVID-19SARS-CoV-2comorbiditiesimmunology and infectious diseasesinflammationinflammatory diseasesrespiratory diseasevirus immunity

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.2K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
107
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
623
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
609
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
112